THOMAS G EVANS, M.D.
Osteopathic Medicine at Technology Sq, Cambridge, MA
License number
Massachusetts 226370
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
100 Technology Sq, Cambridge, MA 02139
Phone
(617) 871-7698
Personal information
See more information about THOMAS G EVANS at radaris.comName
Address
Phone
47 Princeton St, Leominster, MA 01453
46 Lilly Ln, Dedham, MA 02026
Professional information
Dr. Thomas G Evans, Cambridge MA - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
100 Technology Sq SUITE 1304, Cambridge 02139
(617) 871-7698 (Phone), (617) 871-5719 (Fax)
(617) 871-7698 (Phone), (617) 871-5719 (Fax)
Languages:
English, German
Hospitals:
100 Technology Sq SUITE 1304, Cambridge 02139
Boston Medical Center Corporation
1 Boston Medical Ctr Pl, Boston 02118
Boston Medical Center Corporation
1 Boston Medical Ctr Pl, Boston 02118
Education:
Medical School
University of Virginia / Main Campus
Graduated: 1983
University Calif
Graduated: 1984
University Of Virginia
University of Virginia / Main Campus
Graduated: 1983
University Calif
Graduated: 1984
University Of Virginia
Influenza Virus Vaccine Composition And Methods Of Use
US Patent:
7537768, May 26, 2009
Filed:
Feb 9, 2007
Appl. No.:
11/704251
Inventors:
Catherine J. Luke - Frederick MD, US
Adrian Vilalta - San Diego CA, US
Mary K. Wloch - San Diego CA, US
Thomas G. Evans - Cambridge MA, US
Andrew J. Geall - Littleton MA, US
Gretchen S. Jimenez - San Diego CA, US
Adrian Vilalta - San Diego CA, US
Mary K. Wloch - San Diego CA, US
Thomas G. Evans - Cambridge MA, US
Andrew J. Geall - Littleton MA, US
Gretchen S. Jimenez - San Diego CA, US
Assignee:
Vical Incorporated - San Diego CA
International Classification:
A61K 39/145, C07K 14/11
US Classification:
4241861, 4242091, 4352351, 530350
Abstract:
The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.
Severe Acute Respiratory Syndrome Dna Compositions And Methods Of Use
US Patent:
8080642, Dec 20, 2011
Filed:
May 12, 2004
Appl. No.:
10/843656
Inventors:
Adrian Vilalta - San Diego CA, US
Thomas G. Evans - Cambridge MA, US
Melanie W. Quong - San Diego CA, US
Marston Manthorpe - San Diego CA, US
Thomas G. Evans - Cambridge MA, US
Melanie W. Quong - San Diego CA, US
Marston Manthorpe - San Diego CA, US
Assignee:
Vical Incorporated - San Diego CA
International Classification:
C07H 21/02, C12N 15/00, C12Q 1/68
US Classification:
536 231, 4353201, 435 6
Abstract:
The present invention is directed to raising a detectable immune response in a vertebrate by administering in vivo, into a tissue of the vertebrate, at least one polynucleotide comprising one or more regions of nucleic acid encoding a SARS-CoV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to raising a detectable immune response in a vertebrate by administering, in vivo, into a tissue of the vertebrate, at least one SARS-CoV protein or a fragment, a variant, or derivative thereof. The SARS-CoV protein can be, for example, in purified form. The polynucleotide is incorporated into the cells of the vertebrate in vivo, and an immunologically effective amount of an immunogenic epitope of a SARS-CoV polypeptide, fragment, variant, or derivative thereof is produced in vivo. The SARS-CoV protein is also administered in an immunologically effective amount.
Influenza Virus Vaccine Composition And Methods Of Use
US Patent:
7785603, Aug 31, 2010
Filed:
Mar 9, 2007
Appl. No.:
11/715973
Inventors:
Catherine J. Luke - Frederick MD, US
Adrian Vilalta - San Diego CA, US
Mary K. Wloch - San Diego CA, US
Thomas G. Evans - Cambridge MA, US
Andrew J. Geall - Littleton MA, US
Gretchen S. Jimenez - San Diego CA, US
Adrian Vilalta - San Diego CA, US
Mary K. Wloch - San Diego CA, US
Thomas G. Evans - Cambridge MA, US
Andrew J. Geall - Littleton MA, US
Gretchen S. Jimenez - San Diego CA, US
Assignee:
Vical Incorporated - San Diego CA
International Classification:
A61K 39/145, A61K 31/7088, C12N 15/44, C12N 15/36
US Classification:
4242091, 514 44 R, 536 2372, 4353201
Abstract:
The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.